Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with glaucoma and other diseases of the eye, announced today
the acceleration of the expected timeline for reporting efficacy results
from the Company’s 400-patient Phase 3 registration trial (“Rocket 1”)
of Rhopressa TM , a novel once-daily, triple-action eye drop
being tested for its ability to lower intraocular pressure (IOP) in
patients with glaucoma or ocular hypertension.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.